Numerous other targets including, inter alia, Egr-1 for Alzheimer's disease [36], hepcidin for anaemia of chronic disease [37] and WEE1 for myeloid and lymphoid leukaemia [38] have been suggested following studies on THP-1 cells and effective and non-perturbing delivery agents to such cells are therefore highly sought after. Here, HAMP is linked to lymphoid leukemia.